Birmingham: A small study that compared the lungs of cigarette smokers with e-cigarette smokers found that e-cigarette smokers had more lung inflammation than those who smoked tobacco. The pilot study, published in The Journal of Nuclear Medicine, is the first to use PET imaging to compare smokers' lungs with vapers' lungs.
E-cigarettes are now much more than new smoking cessation tools, they are big business. The global e-cigarette or vape market value has increased from USD 1.7 billion in 2013 (GBP 1.4 billion) to an estimated all-time high of USD 24.6 billion in 2022 (GBP 20.8 billion). This massive increase in sales reflects an increase in usage beyond the ex-smoker market. Youth uptake is also at an all-time high. Current figures suggest one in ten middle- to high-school students in the US uses an e-cigarette.
Understanding the effects that e-cigarettes have on the lungs is essential for doctors to prepare for the future. Tobacco cigarettes were originally regarded as an aid to a healthy lifestyle. This poor understanding persisted while scientific evidence battled with economic interest from big tobacco companies, before the actual devastating effects of smoking were revealed decades too late. This same economic interest persists today, so it is vital for scientists to examine all the emerging evidence to ensure history does not repeat itself.
Many of the studies of e-cigarettes have so far looked at the effects of the vapour on immune cells in vitro (in a dish). These experiments show that immune cells that are normally involved in inflammation don't function as they should, which might cause damage to the lungs. Macrophages, immune cells that are in human lungs and help to digest bacteria and regulate inflammation, have been shown to cause more inflammation when exposed to e-cigarette vapour.
This latest pilot study, from researchers at the University of Pennsylvania, examined lung inflammation in people who have vaped, those who smoked cigarettes, and non-smokers. They used positron emission tomography (PET) imaging to examine the participants' lungs. This involves using tracer molecules, and is usually used in cancer diagnosis.
In this case, the tracer targeted an enzyme called inducible nitric oxide synthase, or iNOS. This enzyme is involved in the production of nitric oxide in the body a gas that triggers inflammation. People with asthma and Chronic Obstructive Pulmonary Disease (COPD) have high levels of inflammation and iNOS. Participants inhale the tracer, which binds to the enzyme. This can then be detected by the radioactivity receiver. Following this, images can be compared to determine how much tracer has bound in the lungs of smokers, vapers and non-smokers.